Jara Rubio R., Martinez-Mellado A.J., Kiwitt-Cárdenas J., Clavel J.G., García-Perez B., Castro P., Diaz-Ricart M., Carrillo-Alcaraz A., López-Bernús A., Bernal Morell E., Roura A., Marín S., Ruiz-López F.J., Solana-Martinez E., Martinez-Baño D., Albacete Moreno C.L., Andreu Soler E., Tellez Santoyo A., Fernández Méndez S., Noguera Velasco J.A., Cebreiros Lopez I., Parrilla A., Espuny-Miró A., García-Bernal D., Blanquer M., Sánchez-Salinas A., Iniesta F., Hernandez Garcia C., Muro M., Minguela Puras A., Moreno-Docón A., Torres-Cantero A.M., Munoz Garcia M., Serrano M., Iacobelli M., Carlo-Stella C., Wei L.J., Richardson P.G., Moraleda J.M. Phase IIB, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID-19. European Journal of Haematology. 2026. 10.1111/ejh.70214
AÑO: 2026; IF: 2.6
